European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Blood

• Publication date

  2013-08-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2013-05-501569PMID 23803709PMCID PMC4915804
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors

  2014cited by this paper
• Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance

  2013cited by this paper
• The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib

  2013cited by this paper
• Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis

  2013cited by this paper
• Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain.

  2013cited by this paper
• Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis

  2013cited by this paper
• Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia.

  2013cited by this paper
• Chronic myelogenous leukemia, version 1.2014: Featured updates to the NCCN guidelines

  2013cited by this paper
• Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

  2013cited by this paper
• Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic‐phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

  2013cited by this paper
• The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.

  2013cited by this paper
• BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.

  2013cited by this paper
• Pharmacokinetic–pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia

  2013cited by this paper
• Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty

  2013cited by this paper
• Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

  2013cited by this paper
• Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

  2013cited by this paper
• Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib

  2013cited by this paper
• The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

  2013cited by this paper
• Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.

  2013cited by this paper
• Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

  2013cited by this paper
• Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study

  2013cited by this paper
• How I treat CML blast crisis.

  2012cited by this paper
• Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.

  2012cited by this paper
• Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.

  2012cited by this paper
• Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.

  2012cited by this paper
• Dasatinib inhibits proinflammatory functions of mature human neutrophils

  2012cited by this paper
• Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy

  2012cited by this paper
• A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

  2012cited by this paper
• Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects the Evolution of Polyclonal and Compound BCR-ABL Mutations in Patients Who Relapse On Kinase Inhibitor Therapy

  2012cited by this paper
• Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study

  2012cited by this paper
• Secondary Malignancies in CML Patients – Data From the German CML Study IV

  2012cited by this paper
• A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

  2012cited by this paper
• Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

  2012cited by this paper
• Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

  2012cited by this paper
• Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients with Resistance or Intolerance to BCR-ABL Tyrosine Kinase Inhibitors: Radotinib Phase 2 Clinical Trial

  2012cited by this paper
• Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression.

  2012cited by this paper
• Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

  2012cited by this paper
• Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.

  2012cited by this paper
• Clinical cardiac safety profile of nilotinib

  2012cited by this paper
• Relationship Between Molecular Responses and Disease Progression in Patients (Pts) Treated First Line with Imatinib (Im) Based Regimens: Impact of Treatment Arm within the French Spirit Trial From the French CML Group (FI LMC)

  2012cited by this paper
• Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

  2012cited by this paper
• Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T 315 I mutation

  2012cited by this paper
• Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data

  2012cited by this paper
• Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study

  2012cited by this paper
• Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

  2012influential reference
• Ponatinib in refractory Philadelphia chromosome-positive leukemias.

  2012cited by this paper
• Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation

  2012cited by this paper
• Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients)

  2012influential reference
• Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML.

  2012cited by this paper
• Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.

  2012cited by this paper
• A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

  2012cited by this paper
• Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.

  2012cited by this paper
• Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients

  2012cited by this paper
• How I treat childhood CML.

  2012cited by this paper
• Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.

  2012cited by this paper
• Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

  2012cited by this paper
• Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

  2012influential reference
• Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

  2012influential reference
• Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.

  2012cited by this paper
• The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate.

  2012cited by this paper
• Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

  2012cited by this paper
• Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase

  2012cited by this paper
• Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

  2012cited by this paper
• The International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped-Study): Objectives and Preliminary Results

  2012cited by this paper
• The shady side of dasatinib.

  2012cited by this paper
• Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

  2012influential reference
• Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

  2012cited by this paper
• Off-target effects of BCR–ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia

  2012cited by this paper
• Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.

  2011cited by this paper
• BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

  2011influential reference
• Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

  2011cited by this paper
• Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.

  2011cited by this paper
• Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.

  2011cited by this paper
• Three decades of transplantation for chronic myeloid leukemia: what have we learned?

  2011cited by this paper
• Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia

  2011cited by this paper
• Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase.

  2011influential reference
• Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

  2011influential reference
• Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party.

  2011influential reference
• Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

  2011cited by this paper
• Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.

  2011influential reference
• Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.

  2011cited by this paper
• Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease.

  2011cited by this paper
• Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.

  2011cited by this paper
• Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

  2011cited by this paper
• Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

  2011cited by this paper
• Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.

  2011cited by this paper
• Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.

  2011cited by this paper
• Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed.

  2011cited by this paper
• Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.

  2011cited by this paper
• Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?

  2011cited by this paper
• Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia

  2011cited by this paper
• Nilotinib treatment‐associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front‐line therapy for chronic myelogenous leukemia

  2011cited by this paper
• Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.

  2011cited by this paper
• Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

  2011cited by this paper
• Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008.

  2011cited by this paper
• Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.

  2011cited by this paper
• Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities

  2011cited by this paper
• Severe peripheral arterial disease during nilotinib therapy.

  2011cited by this paper
• Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

  2011cited by this paper
• Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 – a report from the population‐based CAMELIA Registry

  2011influential reference

• Genetic Analysis of Imatinib Resistance in CML: The Role of T315I and E255K

  2026cites this paper
• A krónikus myeloid leukémia magyarországi ellátási gyakorlatának aktuális javaslata

  2026cites this paper
• Phase 3 Clinical Trial of 300 mg Vamotinib Directly Compared with High-Dose Imatinib in Chronic Myeloid Leukemia Patients in Chronic Phase with Failure of Standard-Dose Imatinib: Interim Analysis

  2026cites this paper
• What Should Be the Definition of “Remission” in Pulmonary Arterial Hypertension?

  2026cites this paper
• Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real‐life Italian multicenter study

  2026cites this paper
• Nilotinib‐Induced Retinal Artery Thrombosis in a Patient With Chronic Myeloid Leukaemia: A Rare Case

  2026cites this paper
• Targeted therapy in chronic myeloid leukemia with imatinib: A retrospective hospital-based study in Georgia

  2026cites this paper
• Gastrointestinal Stromal Tumors: Histopathological Spectrum, Molecular Subtypes, and Implications for Targeted Therapy

  2026cites this paper
• Toward the future management of patients with CML and Ph + ALL: real-world safety insights from dasatinib pharmacovigilance

  2026cites this paper
• 慢性髓性白血病患者停用酪氨酸激酶抑制剂后停药综合征和心理问题的发生及其影响因素

  2025cites this paper
• Chronic Myeloid Leukemia in a Young Adult

  2025cites this paper
• A retrospective evaluation of chronic myeloid leukemia patients treated with imatinib

  2025cites this paper
• Ferroptosis: a novel therapeutic warrior in the battle against leukemia

  2025cites this paper
• Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia.

  2025cites this paper
• Cytogenetic Response to Asciminib in Chronic Myeloid Leukemia With the e19a2 Micro BCR::ABL1 Transcript: A Case Report

  2025cites this paper
• Evaluation of leukemic stem cell (CD26 +) in chronic myeloid leukemia patients with different molecular responses and in treatment-free remission

  2025cites this paper
• NK cell-based immunotherapy strategies for myeloid leukemia

  2025cites this paper
• 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

  2025cites this paper
• The role of METTL14 in the progression of chronic myeloid leukemia

  2025cites this paper
• Identification of a PAK6-Mediated MDM2/p21 Axis That Modulates Survival and Cell Cycle Control of Drug-Resistant Stem/Progenitor Cells in Chronic Myeloid Leukemia

  2025cites this paper
• Phase Ib Study of Enzalutamide with Venetoclax in Patients with Metastatic Castration-Resistant Prostate Cancer

  2025cites this paper
• Comparative Clinical Outcomes and Safety of Generic Versus Original Imatinib in the Treatment of Chronic Myeloid Leukemia: A Real-World Cohort Study from Thailand

  2025cites this paper
• Exosomal miRNA expression profiling in patients with imatinib resistant Chronic myeloid leukemia: A pilot study

  2025cites this paper
• An Automated Cartridge-Based Microfluidic System for Real-Time Quantification of BCR::ABL1 Transcripts in Chronic Myeloid Leukemia: An Italian Experience

  2025cites this paper
• Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia

  2025cites this paper
• Epigenetic silencing of DDIT3 gene and its relationship with imatinib resistance, disease progression and smoking status among patients with chronic myeloid leukemia

  2025cites this paper
• T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy

  2025cites this paper
• Real-World Experience in the Management of Chronic Myeloid Leukemia Patients Focused on Tyrosine Kinase Inhibitors Intolerance and Health-Related Quality of Life

  2025influential citation
• AI-Driven Identification and Validation of RXFP1 as a CML Biomarker Using Gene Expression and Integrated GUI Tools

  2025cites this paper
• Early BCR::ABL1 Reduction as a Predictor of Deep Molecular Response in Pediatric Chronic-Phase Chronic Myeloid Leukemia

  2025cites this paper
• [Guideline for the diagnosis and treatment of chronic myeloid leukemia in China (2025)].

  2025cites this paper
• Integrating New Therapies for the Treatment of Chronic-Phase Chronic Myeloid Leukemia

  2025cites this paper
• How I Treat Advanced Phases of CML.

  2025cites this paper
• The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon‐α2b in newly diagnosed chronic phase chronic myeloid leukaemia

  2025cites this paper
• First-line tyrosine kinase inhibitor response in chronic myeloid leukemia: A retrospective study from Iraqi Kurdistan

  2025cites this paper
• Association of fibronectin 1 deregulation with tyrosine kinase inhibitor resistance in chronic myeloid leukemia

  2025cites this paper
• ERRATUM: Synergistic Inhibition of Chronic Myeloid Leukemia: Combining Imatinib and Naringin to Overcome Drug Resistance

  2025cites this paper
• The Efficacy and Safety of Asciminib in the Treatment of Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis

  2025cites this paper
• Favorable outcomes of de novo advanced phases of pediatric chronic myeloid leukemia in the tyrosine kinase inhibitor era

  2025cites this paper
• Assessing endothelial cytotoxicity induced by tyrosine kinase inhibitors: insights from Raman and fluorescence imaging.

  2025cites this paper
• No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level

  2025cites this paper
• Improving the Diagnosis and Follow‐Up of Chronic Myeloid Leukemia Using Conventional and Molecular Techniques

  2025cites this paper
• Role of genetic factors in imatinib resistance of chronic myeloid leukemia: P53, RB1, ASS1 gene deletions, and chromosome 8 hyperdiploidy.

  2025cites this paper
• Unusually Indolent CML: Absence of Complete Cytogenetic Response after 10 Years of Tyrosine Kinase Inhibitor Therapy.

  2025cites this paper
• Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia

  2025cites this paper
• Assessment of retinal, choroidal and peripapillary microvascular changes in patients with chronic myeloid leukemia

  2025cites this paper
• Potential signaling pathways, biomarkers, natural drugs, and chronic myeloid leukemia therapeutics

  2025cites this paper
• Comparing therapeutic effects across tyrosine kinase inhibitors: Chronic myeloid leukemia outcomes and analysis of influencing factors

  2025cites this paper
• Rapid development of Philadelphia chromosome-negative AML in a CML patient with sustained major molecular response to tyrosine kinase inhibitor therapy

  2025cites this paper
• How I Manage Chronic Myeloid Leukemia During Pregnancy.

  2025cites this paper
• Sequential occurrence of BCR::ABL1-negative MPN and CML and vice versa: results from a real world cohort

  2025cites this paper
• BCR::ABL1 kinase domain mutations and their predictive value for treatment outcomes in patients with chronic myeloid leukemia treated with first-line imatinib in a low-income setting: Experience from Côte d’Ivoire

  2025cites this paper
• Semaglutide treatment for type 2 diabetes in a patient with chronic myeloid leukemia: A case report and review of the literature

  2025cites this paper
• Prognostic scoring systems in chronic myeloid leukaemia

  2025cites this paper
• Association between nilotinib-induced hyperbilirubinemia and UGT1A1 polymorphisms in a chronic myeloid leukemia patient

  2025cites this paper
• Synthesis and biological evaluation of oleanolic acid derivatives as potential c-kit inhibitors

  2025cites this paper
• Cytogenetic profile of chronic myeloid leukaemia patients resistant to imatinib at tertiary level in Indonesia

  2025cites this paper
• Dual Targeting of Smoothened, a Key Regulator in the Hedgehog Pathway, and BCR-ABL1 Effectively Eradicates Drug-Insensitive Stem/Progenitor Cells in Chronic Myeloid Leukemia

  2025cites this paper
• Clinical features and treatment response to TKIs in chronic myeloid leukemia patients with atypical BCR::ABL1 transcripts.

  2025cites this paper
• miR-17-92 and miR-203A clusters as predictors of the clinical course of chronic myeloid leukemia

  2025cites this paper
• Causal relationship between serum metabolites and chronic myeloid leukemia: A bidirectional Mendelian randomization study

  2025cites this paper
• Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint

  2025cites this paper
• Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL

  2025cites this paper
• Microfluidic single-cell drug screening: toward personalized precision therapy in chronic myeloid leukemia.

  2025cites this paper
• A cohort study of molecular response to Imatinib in patients with chronic-phase chronic myeloid leukemia in Azerbaijan

  2025influential citation
• Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase

  2025cites this paper
• Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation.

  2025cites this paper
• Chronic Myelogenous Leukemia Patients on Tyrosine Kinase Inhibitors—Hematological Changes and Correlation with European Leukemia Network Response Criteria

  2025cites this paper
• Study of the association between HDAC8, SIRT1, and P53 gene expression with drug resistance in chronic myeloid leukemia patients

  2025cites this paper
• Synergistic Inhibition of Chronic Myeloid Leukemia: Combining Imatinib and Naringin to Overcome Drug Resistance

  2025cites this paper
• Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes

  2024cites this paper
• Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group

  2024cites this paper
• JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib

  2024cites this paper
• Analytical Performance Evaluation of a Digital Real‐Time PCR for Quantifying Major BCR::ABL1 Transcripts

  2024cites this paper
• THE ROLE OF MOLECULAR OR CYTOGENETIC RESPONSE AS A FAVORABLE PROGNOSTIC FACTOR BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA.

  2024cites this paper
• Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: implications for therapeutic response and monitoring

  2024cites this paper
• Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study

  2024cites this paper
• Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.

  2024cites this paper
• A retrospective case-control study for Clinical Validation of mutated ZNF208 as a novel biomarker of fatal blast crisis in Chronic Myeloid Leukemia

  2024cites this paper
• Impact of MDR-1 Gene Polymorphism (rs1128503) on Response to Imatinib or Nilotinib in Iraqi Patients with Chronic Myeloid Leukemia: An Observational Study

  2024cites this paper
• Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes

  2024cites this paper
• Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry

  2024influential citation
• Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices

  2024cites this paper
• Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignancies

  2024cites this paper
• A Retrospective Analysis of BCR-ABL-1 Kinase Domain Mutations in Frontline TKI Resistant Chronic Myeloid Leukemia Patients: A Single Centre Experience

  2024cites this paper
• Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel.

  2024cites this paper
• Diagnosis, Prognostic Factors and Assessment of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel.

  2024cites this paper
• Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients

  2024cites this paper
• Three-way Philadelphia Translocation [t(46, XX, t(9;22;16) (q34;q11.2;q24)] in Chronic Myeloid Leukemia: A Report of Two Cases with Review of the Literature.

  2024cites this paper
• The Contemporary Role of Hematopoietic Stem Cell Transplantation in the Management of Chronic Myeloid Leukemia: Is It the Same in All Settings?

  2024cites this paper
• How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to R.P. Gale and J. Chen

  2024cites this paper
• Computational modeling reveals key factors driving treatment-free remission in chronic myeloid leukemia patients

  2024cites this paper
• Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.

  2024cites this paper
• Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia

  2024cites this paper
• Crisis blástica de células dendríticas plasmocitoides y crisis blástica megacarioblástica en dos pacientes con leucemia mieloide crónica: reporte de casos.

  2024cites this paper
• Early Molecular Response to Imatinib First-Line Therapy and Predictive Factors of Poor Outcomes for Chronic Myeloid Leukemia Patients in Côte d'Ivoire

  2024cites this paper
• Tyrosine Kinase Inhibitor Treatment Patterns in Patients With Chronic-Phase Chronic Myeloid Leukemia: A Single Center Data From China.

  2024cites this paper
• Patient‐reported outcomes in adults with tyrosine kinase inhibitor‐resistant chronic myeloid leukemia receiving olverembatinib therapy

  2024cites this paper
• Clinical outcomes in patients in any phase of CML treated with ponatinib in France—Data from the TOPASE observational study

  2024cites this paper
• Is there really an accelerated phase of chronic myeloid leukaemia at presentation?

  2024cites this paper